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Abstract
Pertussis, or whooping cough, is an important respiratory infection caus-
ing considerable infant mortality worldwide. Recently, incidence has risen in
countries with strong vaccine programmes and there are concerns about anti-
genic shift resulting in vaccine evasion. Interactions between pertussis and
non-vaccine-preventable strains will play an important role in the evolution
and population dynamics of pertussis. In particular, if we are to understand
the role strain replacement plays in vaccinated settings, it will be essential to
understand how strains or variants of pertussis interact. Here we explore un-
der what conditions we would expect strain replacement to be of concern in
pertussis. We develop a dynamic transmission model that allows for coinfec-
tion between Bordetella pertussis (the main causative agent of pertussis) and a
strain or variant unaffected by the vaccine. We incorporate both neutrality (in
the sense of ecological/population genetic neutrality) and immunity into the
model, leaving the specificity of the immune response flexible. We find that
strain replacement may be considerable when immunity is non-specific. This is
in contrast to previous findings where neutrality was not considered. We con-
clude that the extent to which models reflect ecological neutrality can have a
large impact on conclusions regarding strain replacement. This will likely have
onward consequences for estimates of vaccine efficacy and cost-effectiveness.
Keywords: Bordetella pertussis, strain replacement, coinfection, competition,
epidemic, specific immunity
1 Introduction
Whooping cough, or pertussis, is an important respiratory infection. Approximately
16 million cases and 195,000 deaths among children occur annually worldwide [39].
Pertussis is caused predominantly by the bacteria Bordetella pertussis that resides
in the upper respiratory tract and is commonly spread through the secretion of
small droplets from a host being transmitted to a susceptible individual. Typical
symptoms include the classic paroxysmal cough preceding the ‘whooping’ intake of
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breath, sometimes followed by vomiting; this cough can last for up to 8 weeks and in
some cases even longer. Household studies have found that there are high levels of
mild symptoms and asymptomatic carriage, particularly in adolescents and adults
[13, 24, 31]. This leads to under-reporting and poses a risk to younger children
and infants who are unknowingly exposed and who are more susceptible to severe
symptoms and increased risk of mortality.
Incidence of pertussis has recently seen a marked rise in developed countries with
long-running, high-coverage vaccine programmes [8, 23]. There is also evidence that
the age profile of the cases has changed [6, 41], with higher incidence in teenagers
and adults, for what was previously thought of as a childhood disease. Tests into the
efficacy of the acellular vaccine have produced variable results [19, 38, 43], and there
have been suggestions that the increases in incidence are the result of antigenic shift
in B. pertussis, allowing evasion of vaccine-acquired immunity [35, 36]. However,
there are also other sources of genetic variation [17, 21].
The related bacterial strain Bordetella parapertussis causes similar symptoms to
B. pertussis, though parapertussis symptoms are generally less severe. The relation-
ship between B. pertussis and B. parapertussis is not clear [18, 14]. As differential
diagnosis has no effect on clinical treatment, clinicians rarely specifically test for B.
parapertussis, and the reported percentage of pertussis cases caused by B. parapertus-
sis varies, with studies in Europe suggesting it ranges from 2% to 36% [4, 20, 27, 33]
and a large study in the US reporting 14% of pertussis cases identified as B. para-
pertussis [9]. There is considerable debate on the level of immunity that infection
with one of these strains confers against the other. A range of studies have found
that the acellular and whole-cell vaccines protect against pertussis more strongly
than they do against parapertussis [44, 12, 22]. Watanabe and Nagai [42] found
that mice infected with either strain were able to clear both, when re-infected with
both strains six weeks after their initial infection. More recent work found that acel-
lular vaccination cleared B. pertussis, but led to a large increase in B. parapertussis
colony-forming units in co-infected rodents, suggesting strong inter-strain competi-
tion [30] within hosts. In 2008, Restif et al. [40] developed a mathematical model
of B. pertussis and B. parapertussis allowing for coinfection, to analyse the effect
of asymmetric cross-immunity between the strains. Their model suggested that the
pertussis vaccine would have little effect on the prevalence of B. parapertussis.
Similar strains of a pathogen can be expected to compete for hosts and/or to
compete for resources within hosts. When strains are competing for resources, we
would expect that selectively reducing the prevalence of one of them would lead to
rises in the other one, as more resources become available (as was found, within
hosts, in the rodent study [30] mentioned above). Inter-strain competition for hosts
is modulated by immunity: a vaccine can lead to strain replacement by selectively
protecting hosts from a primary strain, allowing a non-vaccine strain to access more
hosts than it would otherwise. This can undermine the efficacy and cost-effectiveness
of vaccination programmes. Accordingly, in using models to explore whether strain
replacement is a concern in a particular setting, it is helpful to determine the likely
mechanisms by which the strains may be in competition with each other and explore
how these play out using mathematical models.
Some of us have previously argued that models exploring inter-strain interactions
should behave in a sensible way in the limit when the strains are identical [28, 11]. In
particular, a rare strain should not have a reproductive advantage simply by virtue
of being rare. If it has such an advantage, there is so-called “coexistence for free”
– in the limit in which strains are identical, rare strains are given a competitive
advantage in the model, despite being identical to the more common strain. This
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reproductive advantage is nonsensical, as each identical individual in a population
should have the same number of descendants on average. Models that permit this
“identical behaviour of identical strains” (and do not feature coexistence for free) can
be called “neutral null models” (or, here, simply “neutral”). Many mathematical
models of multiple circulating strains do not allow identical behaviour of identical
strains [28]; the resulting implicit assumptions about competition in these models
have potentially large consequences for conclusions about vaccine-induced strain
replacement (compared to models that do allow neutral interactions). For example,
the B. pertussis/B. parapertussis model by Restif et al. [40] does not meet the
neutral null criterion, and so may promote the coexistence of both B. pertussis and
B. parapertussis, reducing the model’s inter-strain competition.
It is challenging to incorporate immunity and vaccination into the neutral frame-
work, because if immunity is entirely non-specific, then the strains are not mean-
ingfully different from the point of view of vaccination, but if immunity is specific,
a model will fail the neutral test. Furthermore, including immunity in the neu-
tral framework in a compartmental, SIR-type, model requires adding a number of
compartments reflecting individuals who are susceptible, infected or recovered with
one strain and immune to the other. Accordingly, we set out to construct the sim-
plest model with the following ingredients: (1) satisfies the neutral null criteria
when strains are identical; (2) contains vaccination specific to one strain (when they
are not identical); (3) contains immunity, which, reflecting the uncertainty around
specificity in pertussis, can be more or less specific to each strain (when they are not
identical). We develop a neutral model of B. pertussis interacting with a non-vaccine
strain (which could be B. parapertussis, if the model is parameterised appropriately).
We include vaccination and immunity, where the immune specificity is parameter-
ized such that the model is neutral when the strains are indistinguishable. We allow
neutrality to be broken by the introduction of strain-specific immunity, and we ex-
plore the relationship between the specificity of immunity and the extent of strain
replacement due to vaccination.
2 Methods
Modeling strategy
We developed a compartmental SIR-type model, allowing for coinfection and immu-
nity. Both our model and the model by Restif et al. [40] incorporate coinfection,
and we note that if coinfecion is not included, this amounts to an assumption that
strains are competing strongly for hosts. This assumption would drive models to-
wards strain replacement because under strong competition for hosts, reducing the
prevalence of one strain makes hosts available to the other. Consequently, our model
is based on the neutral null model proposed by Lipsitch et al. [28], in which indi-
viduals can become coinfected with both strains, or dually infected with the same
strain. Neutrality requires that coinfected individuals can have one strain “knocked
out” by the other (strain replacement). Otherwise, a rare strain has an advantage
by virtue of being rare [11, 28]. In our model, infection with a second strain results
in coinfection rather than super-infection, because super-infection (one strain en-
tirely and instantly displacing the other) is a strong assumption about inter-strain
competition. We also add a ‘recovered’ compartment, R, representing individuals
who have acquired immunity to both strains (Figure 1a).
Specific immunity cannot be included when verifying whether a model meets
the neutral null criteria for identical strains, as immunity to one strain and not
the other requires a difference between the strains. Furthermore, if there is specific
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immunity, then a rare strain will have an advantage over a prevalent strain due
to the population’s partial immunity (only) to the prevalent strain. When a rare
strain has an advantage due to being rare, this will promote stable coexistence of
the two strains. To explore this spectrum of competition, we begin with a neutral
null model and build specific immunity on top of it. The result is a model that
reduces to a neutral null model when strains are indistinguishable. To do this, we
make the assumption that when individuals gain specific immunity to one strain,
they can still become either singly or dually infected with the other. Therefore we
require compartments to represent individuals who have recovered from one of the
strains and are now: 1) susceptible to the other strain, 2) infected with the other
strain or 3) dually infected with the other strain. This introduces six additional
compartments to the model (compared to the six-state model with coinfection in
[28]) and gives the structure shown in Figure 1b.
Neither a neutral model nor a model requiring specific immunity can be used to
study the interplay between neutrality, specific immunity and strain replacement, as
the neutral null model has no specific immunity and the model with specific immu-
nity is not neutral. We therefore introduce a parameter s to smoothly interpolate:
s ∈ [0, 1] is a parameter that shows the extent of strain specific immunity present in
the model (Figure 2). When s = 1 there is specific immunity and the model reduces
to the model in Figure 1b, which is not neutral. When s = 0 there is no specific
immunity and the model reduces to the model in Figure 1a, which is neutral. When
0 < s < 1, the model reflects the presence of some strain-specific immunity as well
as some non-specific immunity. For simplicity, we assume symmetric inter-strain
interactions except for the asymmetry in the transmission and response to vacci-
nation. As a result, s appears to have a number of distinct effects in the model,
but these are all one effect: smoothly interpolating between a neutral model and a
non-neutral one with specific immunity.
We make the following assumption about immunity: when individuals are singly
or dually infected with one strain, on recovery, they are either fully protected against
reinfection with the same strain (specific immunity) or fully protected against both
strains (non-specific immunity). As a result, the recovery rate r is multiplied by s
when immunity is specific and by 1 − s when immunity is non-specific. The same




The differential equations are:
dS
dt
= µ(1− ν − S)− (λp + λn)S + γpSRp + γnSRn + (1− s)γR
dIp
dt
= −µIp + λpS − rIp − kspλpIp − kcpλnIp + γnIpRn
dIn
dt
= −µIn + λnS − rIn − ksnλnIn − kcnλpIn + γpInRp
dIpn
dt




= −µIpp + kspλpIp + ckcnλpIpn − 2ckcpλnIpp − rIpp + γnIppRn
dInn
dt
= −µInn + ksnλnIn + ckcpλnIpn − 2ckcnλpInn − rInn + γpInnRp
dSRp
dt
= µ(ν − SRp) + sr(Ip + Ipp)− kcpλnSRp − γpSRp + sγnR
dInRp
dt
= −µInRp + kcpλnSRp − ksnλnInRp − γpInRp − rInRp
dInnRp
dt
= −µInnRp + ksnλnInRp − rInnRp − γpInnRp
dSRn
dt
= −µSRn + sr(In + Inn)− kcnλpSRn − γnSRn + sγpR
dIpRn
dt
= −µIpRn + kcnλpSRn − kspλpIpRn − γnIpRn − rIpRn
dIppRn
dt
= −µIppRn + kspλpIpRn − rIppRn − γnIppRn
dR
dt
= −µR+ r(Ipn + IpRn + IppRn + InRp + InnRp)− s(γp + γn)R
−(1− s)γR+ (1− s)r(Ip + Ipp + In + Inn)
where:
λp = βp(Ip + IpRn + qIpn + 2q(Ipp + IppRn))
λn = βn(In + InRp + qIpn + 2q(Inn + InnRp))
The states and variables are defined in full in Table 1.
Parameters and simulation
Due to the high dimensionality of the model, little algebraic analysis is feasible
and we take a simulation approach. Prevalences reported in figures are numerically-
determined equilibria of the model except for the trajectories in Figure 3. The model
was parameterised according to the literature wherever possible. All programming
and analysis was performed using MATLAB [34], while XPPAUT [15] was used to
solve the differential equations. We introduce a small amount of the non-vaccine
strain at the time at which vaccine is introduced in the simulations, mimicking the
introduction of small amounts of diverse strains in real populations through muta-
tion, acquisition of genetic material, immigration of hosts carrying diverse strains
and so on (these are not explicitly modeled).
Our parameters are based on limited available information from clinical data
and previous modeling works. We set the average infectious period 1r , where r is the
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recovery rate, for both strains to be 20 days [2]. Infection-induced immunity may
often be longer-lasting than vaccine-induced immunity [3, 5], but Cherry [7] argued
that both vaccination- and infection-induced immunity are of similar duration. We
follow this latter assumption for simplicity and clarity. We set the average duration
of immunity 1γ (where γ is the rate of loss of immunity) to be 20 years, which Aguas
et al [1] report is consistent with empirically-determined rates of waning immunity.
Pertussis is a highly contagious disease with very large reproductive number R0 of
12 − 17 [29]. We choose values of R0 from this range for both strains. We also
explore values of R0 that are well below these high estimates to see the effect on our
results. The relationship between the basic reproduction number of a strain, R0i
and its transmission rate, βi is R0i =
βi
µ+r , where 1/µ+ r is the average duration of
infection (taking the lifespan 1/µ into account.
No estimates of the inter-strain interactions kc and kn are available; these were
varied between 0 and 1. We impose symmetry on all rates of secondary infection i.e.
kcn = ksn = ksp = kcp. We also assume that at time t = 0, most of the individuals
in the population are susceptible to both strains i.e. in the class (S), a small but
equal fraction of individuals are singly infected with either strain (Ip or In), and no
individuals in all other classes i.e. initial condtions are, Ip = In = 0.003, S = 0.994
and Inn = Ipp = Ipn = SRp = SRn = IpRn = IppRn = InRn = InnRn = 0 at t = 0.
3 Results
We find that the specificity of the immune response can shift the model from a
regime in which there is no strain replacement and the strains’ population dynamics
are independent of each other to one in which vaccination leads to complete strain
replacement, i.e. where there is no significant change in pre- and post-vaccine preva-
lence of both strains combined. Figure 3 shows the prevalence of B. pertussis and
B. parapertussis in our model with s = 0 , s = 0.5 and s = 1, and in the model
proposed by Restif et al. [40]. When immunity is not strain-specific (s = 0), pertus-
sis vaccination can eliminate pertussis, but the prevalence of the non-vaccine strain
increases to compensate. The result is that the vaccine has no significant impact
on the overall number of cases. In contrast, when immunity is specific, vaccination
has no significant impact on the prevalence of the non-vaccine strain. Intermediate
values of specificity result in outcomes between these two extremes, with moder-
ate increases in the non-vaccine strain after vaccination. In addition, the extent of
immunity to one strain conferred by infection with the other has consequences for
the level of vaccination required to eliminate infection. For example, when s = 0.5
(Figure 3b with s = 0.5), the effect of vaccination on B. pertussis is reduced com-
pared to its effect when s = 0, and a vaccine coverage of 0.95 no longer eliminates
B. pertussis.
Under parameters where non-specific immunity is asymmetric, ie where B. para-
pertussis infection confers some immunity to B. pertussis but not vice versa [40, 44],
we found that the prevalence of B. parapertussis is slightly higher than with the
parameters of Table 1. This is due to the advantage that the asymmetry confers
– those who have prior infection with B. pertussis remain more susceptible to B.
parapertussis than vice versa. However, the bifurcation diagrams are very similar to
those reported here and do not indicate that B. parapertussis would have the ability
to replace B. pertussis following a vaccination programme.
We compared our results to those of Restif et al. [40], who modeled B. pertussis
and B. parapertussis, allowing for coinfection. In their model, rather than interacting
neutrally, identical strains reach a 50/50 equilibrium prevalence independent of their
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initial relative frequencies, meaning that an initially rare (but otherwise identical)
strain has far more descendants than the initially prevalent one. Their model is
similar to our model when s = 1 (specific immunity). Figure 3a shows that both their
model and ours with s = 1 find no strain replacement, as Restif et al. concluded.
However, when immunity is less specific we find considerable strain replacement.
Furthermore, we obtain the same result – higher specificity means less competition
and less replacement – even if we adjust the effect of s in the model to only modify
some of the terms (for example, if the s terms leaving the dually-infected classes are
removed so that s only affects the singly-infected classes, we still find that s = 0
results in strain replacement and that replacement is reduced when s > 0).
We explore the interplay between s, vaccination levels, and the relationship be-
tween the prevalence of the two strains (Figure 4) under parameters reflective of
B. pertussis and B. parapertussis. The steady state prevalences of the two strains
are shown over a range of values of vaccine coverage. As vaccine coverage increases
for the neutral model (s = 0), the prevalence of B. pertussis decreases, but the
prevalence of B. parapertussis increases, and the overall (total) prevalence remains
essentially unchanged. Conversely, in the case where s = 1, vaccination leads to de-
creasing B. pertussis prevalence while B. parapertussis prevalence remains constant.
These results are not specific to B. parapertussis but would apply generically to a
non-vaccine strain.
The bifurcation diagrams in Figure 5 show the equilibrium steady states for the
models, with navy blue indicating no disease, yellow indicating that only B. pertussis
persists, blue indicating that only B. parapertussis persists, and red showing where
both strains stably coexist. When s = 0 (Figure 5a), there is very little coexistence
and the model exhibits competitive exclusion (the strain with the higher R0 value
out-competes the other strain). If s = 0.5 there is generic coexistence; only if the
R0 of one of the strains is low will the other strain persist alone. This is also the
case when s = 1. In addition when s = 1 the two strains are independent, such that
the R0 of one strain has no effect on the prevalence of the other, shown in Figure 5c
by the horizontal and vertical boundaries between the single strain and coexistence
steady states. The model proposed by Restif et al. shows similar horizontal and
vertical boundaries between the single strain and coexistence steady states.
Figure 6 shows how the value of the non-vaccine-strain R0 (B. parapertussis; R0n
in the figure) affects the prevalence of both strains over varying vaccine coverages
and for s = 0, 0.5 and 1. When s = 0 (top left panel) there is a trade-off such that
when one strain’s prevalence is high, the other’s is low. This is an intuitive reflection
of the inter-strain competition. When s = 1, vaccine coverage has little or no effect
on the prevalence of B. parapertussis (bottom right panel). Conversely (top right
panel), the R0 of parapertussis has essentially no effect on pertussis prevalence when
s = 1.
4 Discussion
In any vaccination programme in which there is antigenic diversity of the pathogen,
strain replacement should be of concern. We have illustrated in a mathematical
model that how much of a concern it is depends strongly on the specificity of the
immune response; this shapes the inter-strain interactions. In using models to deter-
mine whether or not strain replacement is probable, modelers must carefully consider
their assumptions about these interactions. Neutral models allow identical strains
to behave identically (independent of their relative prevalence); a consequence of
this is that the relative frequencies of indistinguishable strains should be constant
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in time [28]. This in turn means that if there were more infections of one group,
there would be fewer of another (as relative frequencies sum to 1) – the embodiment
of competition. Models that have “coexistence for free”, i.e. models that contain
some implicit mechanism promoting the long-term stable coexistence of different
strains, also have reduced inter-strain competition. Generally speaking, the more
coexistence-promoting a model is, the less competition exists between its strains.
This has consequences when it comes to making predictions about strain replace-
ment.
Strain replacement is rooted in inter-strain competition. If strains are competing
for hosts and some hosts are protected from one strain but not another by vacci-
nation, the stage is set for strain replacement. Strain replacement can also occur
(in models) where vaccination targets each strain equally but one has an advantage
in super-infecting or re-infecting hosts with the other strain [32]. In contrast, if
infection with a strain is entirely unrelated to current or past infection with another
strain then concern about strain replacement would be unnecessary. But this is
unlikely to be the case for very closely related pathogens.
The fundamental effect underlying our results is that the extent of strain re-
placement depends on whether the underlying model is neutral. This result can
be obtained in a wide range of models. With reference to Figure 5, imagine an
intervention that only targets the strain whose R0 is on the horizontal axis as a
horizontal, left-pointing arrow moving R0 from a higher point to a lower one. In the
neutral null case (top left panel), this arrow can easily move the model from a point
in one single strain region (light blue) to the other single strain region (yellow), i.e.
causing strain replacement. Whether it does so depends on the strength of the in-
tervention, i.e. how much does it reduce R0, and how much higher R0 of the vaccine
preventable strain is than that of the escape strain initially. In the non-neutral cases
where coexistence is generic, such an arrow will generally not move the system across
the bifurcation boundary. Nicoli [37] illustrated these diagrams for a wide range of
neutral and non-neutral models; neutral models generically show the competitive
exclusion-type bifurcation diagram (similar to that shown in [11]) in which the only
prevalent strain is the one with a higher R0.
Recently, Flasche et al [16] also stressed that strain replacement will occur when
immunity is not strain-specific. They note that if a strain limits its own transmission
to the same extent it limits the spread of a competing strain (non-specific immunity),
then coexistence is unlikely. In the same way, in our model, for strain replacement
to occur, there must be some non-specific immunity. It is likely that the true level of
competition between B. pertussis and B.parapertussis lies somewhere between the
competing and independent regimes.
Cross-immunity compared to strain-specific immunity is not the only mecha-
nism for epidemiologically relevant interaction between strains or infections. For
example, differential susceptibility, co-treatment of different infections, differential
symptomaticity (ie differences in virulence and transmissibility) and enhancement
effects such as one strain resulting in increased transmission of the other, would all
affect the interactions between strains. While model structures can be developed
which account for these effects, strain interactions are affected by subtle modeling
choices, and models may inadvertently make strong assumptions that bias conclu-
sions that depend on inter-strain interactions. We suggest that clearly elucidating
how strains interact and why, considering the extent of competition and the na-
ture of coexistence-promoting mechanisms, should be a fundamental part of model
development in this field.
The parameter s moves our model between two extremes, neutrality (competi-
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tion) and strain specific immunity (independence). However, it would be difficult
to infer s from epidemiological data. Vaccination would be a natural experiment
to see what happens and potentially to infer s, but the other complexities and
heterogeneities in such hypothetical studies would make this very challenging. An
alternative approach would be to conduct experiments in animal models to guide
inference on the degree of specific and non-specific immunity [31], but such studies
would have difficulty capturing the long-term and population-level effects of inter-
strain competition. In addition to the difficulty in inferring s from data, limitations
of this work include simplifying assumptions in the model: homogeneous population
mixing, deterministic dynamics, lack of age structure, and so on. Including these
complexities would be expected to change the details of the model trajectories, and
in particular the high-frequency oscillations are likely an artefact of these simpli-
fying assumptions. In addition, at low prevalence, stochastic extinction would be
possible (though if there were also mutation and stochastic generation of diversity,
non-vaccine strains could arise again). However, Nicoli’s work [37] incorporating age
structure into similar models for meningococcus found that the competition effects
– coexistence and replacement – were not changed when age and population mixing
were modified and we believe that our results on competition, replacement and the
specificity of immunity are robust. They are also in accordance with the detailed
individual-based model of pneumococcal diversity of Cobey and Lipsitch [10].
The model we have developed is generic and could be applied to model inde-
pendence and competition in other organisms. For example, it might be assumed,
based on the effect of vaccination programmes, that there are high levels of compe-
tition between strains of Streptococcus pneumoniae [25]; an intermediate value of s
would capture some non-specific immunity while preserving some serotype-specific
immunity (as in Cobey and Lipsitch [10]). For entirely independent strains, as stud-
ies suggest may be the case for Haemophilus influenzae [26], s could be set close
to 1. Furthermore, immune specificity is not the only way to alter the extent of
competition in this model or others. While different choices for the parameters q
(the relative infectiousness of dually infected individuals compared to singly infected
ones) and c (which alters the re-infection dynamics for dually infected individuals)
could make the model non-neutral they could also reflect differing scenarios for how
dual infection plays out. We therefore suggest that this model and those like it are a
helpful framework for understanding how re-infection, dual infection and pathogen
variation at the simplest level of two strains affect the strain frequencies over time.
And while the mechanism and extent of competition between B. pertussis and B.
parapertussis (or other non-vaccine strains) is unknown, clarifying the consequences
of strain interactions at the level of immunity, and other mechanisms that may re-
sult in strain replacement, is very important in understanding how this pathogen is
responding to vaccination.
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5 Figures
(a) Neutral null coinfection model
without specific immunity.
(b) Coinfection model with specific immunity that doesn’t
meet the neutral null criteria.
Figure 1 – Coinfection models with neutrality, but no specific immunity and with
specific immunity, but no neutrality. See Table 1 for parameter definitions
Figure 2 – Coinfection model for B. pertussis and B. parapertussis with variable
specific immunity. See Table 1 for parameter definitions. In particular, throughout
this work, symmetric interactions are assumed such that ksn = ksp = ks, kcn =
kcp = kc.
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(a) R0p = 9, R0n = 7
(b) R0p = 15, R0n = 12
Figure 3 – Trajectory plots of prevalence and incidence for different values of spe-
cific immunity, s. Blue line = pertussis; green line = parapertussis. Introduction of
vaccination at t = 100, vaccine coverage ν = 0.95. Parameters and initial condi-
tions: R0p = 15, R0n = 10, r = 1/20 days, kcn = ksn = ksp = kcp = 0.7, c = 0.5,
q = 0.5, γ = 1/70 years, µ = 1/70 years. At t = 0, Ip = In = 0.003, S = 0.994
and Inn = Ipp = Ipn = SRp = SRn = IpRn = IppRn = InRn = InnRn = 0.
A small amount of non-vaccine strain was introduced when s = 0 mimicking im-
portation by mutation or immigration, at the time of the introduction of vaccine
(In(tvac) = 0.0001). High-frequency oscillations occur as a transient effect in the
model, resulting from instantaneous introduction of high levels of vaccine coverage,
or (at the start of the simulation) the fact that the model has fast time scales in its
relaxation to equilibrium. These high-frequency oscillations would not be expected
to be observed because such sharp transitions (0 to 95% vaccination coverage es-
sentially instantaneously, together with instantaneous homogeneous mixing in the
population) are not realistic.
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(a) Specific Immunity = 0
(b) Specific Immunity = 1
Figure 4 – Prevalence for different levels of vaccine coverage and specific immunity.
Blue surface = pertussis; green surface = parapertussis. [R0p = 7 [40], R0n = 5.6,
r = 1/20 days, kcn = ksn = ksp = kcp = 0.7, c = 0.5, q = 0.5, γ = 1/20 years,
µ = 1/70 years. These parameter values were chosen to reflect similar parameters
to those used by Restif et al. At t = 0, Ip = In = 0.003, S = 0.994 and
Inn = Ipp = Ipn = SRp = SRn = IpRn = IppRn = InRn = InnRn = 0.
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(a) s = 0: Neutral null, no specific im-
munity (b) s = 0.5
(c) s = 1: Specific immunity, not neu-
tral (d) Model by Restif et al.
Figure 5 – Bifurcation diagrams for different values of specific immunity, s. Navy
= no disease; yellow = pertussis only; blue = parapertussis only; red = coexistence.
r = 1/20 days,kcn = ksn = ksp = kcp = 0.7, ν = 0, c = 0.5, q = 0.5, γ =
1/10years, µ = 1/70 years. At t = 0, Ip = In = 0.003, S = 0.994 and Inn =
Ipp = Ipn = SRp = SRn = IpRn = IppRn = InRn = InnRn = 0.
13
(a) s = 0: Neutral (b) s = 0.5 (c) s = 1: Specific immunity
Figure 6 – Bifurcation diagrams of prevalence for varying levels of vaccine coverage
and parapertussis transmission. (a) s = 0: there is a trade-off such that where
pertussis prevalence is low, parapertussis prevalence is high and vice versa. Both
the R0 values and the vaccination rate affect both strains’ prevalence. (b) s = 0.5
Intermediate specificity of immunity reduces the trade-off. (c) s = 1 (specific
immunity): here, the R0 value of the non-vaccine (parapertussi) strain does not
affect pertussis prevalence, and the vaccination rate does not affect the parapertussis
prevalence. Other parameters are: R0p = 12, r = 1/20 days, k = 0.7, c = 0.5,
q = 0.5, γ = 1/10 years, µ = 1/70 years. At t = 0, Ip = In = 0.003, S = 0.994
and Inn = Ipp = Ipn = SRp = SRn = IpRn = IppRn = InRn = InnRn = 0.
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6 Tables
Table 1 – Definitions of all states and parameters
Symbol Definition
States
S Susceptible to both pathogen strains
Ip Infected with pertussis
In Infected with non-preventable strain (Bordetella parapertussis)
Ipn Coinfected with both strains
Ipp Dually infected with pertussis
Inn Dually infected with non-preventable strain
SRp Susceptible to non-preventable, immune to pertussis
InRp Infected with non-preventable, immune to pertussis
InnRp Dually infected with non-preventable, immune to pertussis
SRn Susceptible to pertussis, immune to non-preventable
IpRn Infected with pertussis, immune to non-preventable
IppRn Dually infected with pertussis, immune to non-preventable
R Immune to both strains
Variables
p As underscore: vaccine preventable pertussis
n As underscore: non-vaccine preventable pertussis
λ Force of infection
β Transmission rate (β = R0(µ+ r))
R0 Reproductive number (R0p = 15, 9;R0n = 12, 7)
µ Birth/Death rate (µ = 170years)
ν Vaccination coverage against pertussis (ν = 0.95)
γ Rate of lose of immunity (γ = 120years)
ks Self-protection(ksn = ksp = ks = 0.7)
kc Cross-protection (kcn = kcp = kc = 0.7)
r Recovery rate (r = 120days)
c Probability of replacement with other strain upon successful reinfection (c = 0.5)
q Relative infectiousness of the dual to single infection (q = 0.5)
s Allowing for specific (s = 1) & non-specific immunity (s = 0)
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